PMD Device Solutions’ RespiraSense technology demonstrates ability to predict 7-day mortality

STOCKHOLM, SWEDEN / ACCESSWIRE / September 17, 2024 / PMD Device Solutions (FRA:8T0)(STO:PMDS) PMD Device Solutions AB (Ticker Symbol:PMDS), a leader in digital health technology, today announced the outcome of a recent clinical study that validated the capabilities of its RespiraSense monitoring technology to predict 7-day mortality outcomes.

The 402-patient study demonstrated that 4 hours of continuous respiratory rate monitoring with RespiraSense accurately predicted 7-day mortality (n=22). This sets a new standard for patient monitoring and intervention, particularly in emergency settings where it is critical to determine which patients require admission and which can be safely discharged. The study was conducted between May 18, 2023 and January 31, 2024 at the Emergency Department and Outpatient Clinic of Kitovu Hospital in Masaka, Uganda.